Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation & Amortization (CF) (2020 - 2025)

Insight Molecular Diagnostics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $600000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 88.68% year-over-year to $600000.0; the TTM value through Sep 2025 reached $2.1 million, up 73.36%, while the annual FY2024 figure was $1.5 million, 7.75% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $600000.0 at Insight Molecular Diagnostics, up from $516000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $600000.0 in Q3 2025 and bottomed at $121000.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $384000.0 (2022), against an average of $366578.9.
  • The largest YoY upside for Depreciation & Amortization (CF) was 207.46% in 2021 against a maximum downside of 36.57% in 2021.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $218000.0 in 2021, then soared by 83.49% to $400000.0 in 2022, then fell by 25.0% to $300000.0 in 2023, then surged by 80.33% to $541000.0 in 2024, then rose by 10.91% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Depreciation & Amortization (CF) are $600000.0 (Q3 2025), $516000.0 (Q2 2025), and $484000.0 (Q1 2025).